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De Novo and Inherited Loss-of-Function Variants in
TLK2: Clinical and Genotype-Phenotype Evaluation
of a Distinct Neurodevelopmental Disorder
Margot R.F. Reijnders,1,54 Kerry A. Miller,2,54 Mohsan Alvi,3 Jacqueline A.C. Goos,4 Melissa M. Lees,5
Anna de Burca,6 Alex Henderson,7 Alison Kraus,8 Barbara Mikat,9 Bert B.A. de Vries,1
Bertrand Isidor,10,11 Bronwyn Kerr,12,13 Carlo Marcelis,14 Caroline Schluth-Bolard,15,16
Charu Deshpande,17 Claudia A.L. Ruivenkamp,18 Dagmar Wieczorek,9,19 The Deciphering
Developmental Disorders Study,20 Diana Baralle,21,22 Edward M. Blair,6 Hartmut Engels,23
Hermann-Josef Lu¨decke,9,19 Jacqueline Eason,24 Gijs W.E. Santen,18 Jill Clayton-Smith,12,13
Kate Chandler,12,13 Katrina Tatton-Brown,25 Katelyn Payne,26 Katherine Helbig,27 Kelly Radtke,27
(Author list continued on next page)
Next-generation sequencing is a powerful tool for the discovery of genes related to neurodevelopmental disorders (NDDs). Here, we
report the identification of a distinct syndrome due to de novo or inherited heterozygous mutations in Tousled-like kinase 2 (TLK2) in
38 unrelated individuals and two affected mothers, using whole-exome and whole-genome sequencing technologies, matchmaker da-
tabases, and international collaborations. Affected individuals had a consistent phenotype, characterized by mild-borderline neurode-
velopmental delay (86%), behavioral disorders (68%), severe gastro-intestinal problems (63%), and facial dysmorphism including
blepharophimosis (82%), telecanthus (74%), prominent nasal bridge (68%), broad nasal tip (66%), thin vermilion of the upper lip
(62%), and upslanting palpebral fissures (55%). Analysis of cell lines from three affected individuals showed that mutations act through
a loss-of-function mechanism in at least two case subjects. Genotype-phenotype analysis and comparison of computationally modeled
faces showed that phenotypes of these and other individuals with loss-of-function variants significantly overlapped with phenotypes of
individuals with other variant types (missense and C-terminal truncating). This suggests that haploinsufficiency of TLK2 is the most
likely underlying disease mechanism, leading to a consistent neurodevelopmental phenotype. This work illustrates the power of inter-
national data sharing, by the identification of 40 individuals from 26 different centers in 7 different countries, allowing the identifica-
tion, clinical delineation, and genotype-phenotype evaluation of a distinct NDD caused by mutations in TLK2.The introduction of whole-exome sequencing (WES) as a
diagnostic test for individuals with unexplained neurode-
velopmental disorders (NDDs) has led to the identification
of dozens of disease-associated genes. As a recent example,
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Han G. Brunner,1,33,54,* and Andrew O.M. Wilkie2,48,54,*Arabidopsis gene Tousled.3 TLK2, ubiquitously expressed in
all tissues including fetal brain, encodes a serine/threonine
kinase comprising a catalytic domain and multiple highly
conserved coiled-coil motifs.3,4 TLK2 is known to have
maximal activity during the S-phase of the cell cycle and
is therefore tightly linked to DNA replication.3 DNA dou-
ble-strand breaks lead to rapid and transient inhibition of
TLK activity, suggesting a role in checkpoint regulation.5
With the discovery of both H3-H4 chaperone Asf1 and his-
tone H3 as physiological substrates of TLKs, its protein
function has been linked to chromatin assembly.6–10
To establish the contribution of TLK2 variants to NDDs
in humans, we systematically collected phenotypic data
of the five affected individuals with TLK2 variants reported
previously,1 derived cell lines, and exploited different stra-
tegies to identify additional individuals with a variant in
this gene. By including TLK2 in a Deciphering Develop-
mental Disorders11 Complementary Analysis Project, by
using of GeneMatcher,12 and by sharing data with interna-
tional collaborators, we identified a total of 38 unrelated
individuals and two affected mothers with heterozygous
variants in TLK2. Variants were detected by either family-
based WES (research settings, n ¼ 18 probands and 2
affected parents; diagnostic settings, n ¼ 18 probands) or
whole-genome sequencing (WGS) (research settings,
n ¼ 2 probands) in 26 different institutions and 7 different
countries (Figure S1; Supplemental Subjects and Methods).
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each of whom had a second likely pathogenic mutation
in another gene, were excluded from further consideration
to avoid confounding in the phenotypic analysis (Supple-
mental Subjects and Methods). IRB-approved consents for
WES or WGS in diagnostic or research settings were ob-
tained for all individuals.
We observed a broad spectrum of different variant types
in TLK2 (GenBank: NM_006852): 4 frameshift variants, 10
nonsense variants (including 2 located in the last exon), 12
canonical splice-site variants, and 9 missense variants (Fig-
ures 1A–1C; Table 1). Additionally, we identified a de novo
balanced translocation in one of theWGS case subjects, re-
sulting in a breakpoint at chromosome 17q23.2 disrupting
the TLK2 intron between exons 2 and 3 (Figure 1D; Supple-
mental Subjects and Methods). Interestingly, we found
recurrent mutations within our cohort of affected individ-
uals, occurring at hypermutable sites as reported by
Rahbari et al.13 We considered the alternative possibility
of gene conversion, because pseudogenes very similar to
TLK2 exist at 10p11.21 and/or 17q12; however, the pseu-
dogene sequence(s) at the site of each recurrent mutation
correspond to wild-type TLK2, excluding this mechanism.
The missense variants c.1487A>G (p.His496Arg) and
c.1015C>T (p.Arg339Trp) were each identified in two un-
related individuals, and c.1016G>A (p.Arg339Gln) also oc-
curs at the Arg339 codon (Figure 1C; Table 1). Finally, two
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Figure 1. Intragenic Variants and
Balanced Translocation Identified in TLK2
(A) Location of TLK2 (GenBank: NM_
006852.3) on chromosome 17q23.2 (see
Supplemental Subjects and Methods for
discussion about different TLK2 splice-
forms). Vertical marks in TLK2 represent
the 22 exons. Green arrow indicates region
enlarged in panel below.
(B) Schematic view (not to scale) of
exons 11–22 and locations of 12 identi-
fied splice site mutations (green crosses).
The splice site mutation inherited from
an affected parent is shown in bold and
green. The variant subjected to cDNA
analysis is shown in the dark green rect-
angle.
(C) Overview of TLK2 protein with the
protein kinase domain (dark green) and
three coiled-coil motifs (light green).
Loss-of-function variants (24 total, in-
cluding 8 nonsense, 4 frameshift, and
12 splice site mutations) are shown
above the protein with green crosses
indicating positions of splice site muta-
tions. Other variants (11 missense vari-
ants and 2 nonsense variants causing
a premature stop codon in the last
exon) are shown below the protein. The
frameshift mutation inherited from an
affected parent is shown in bold and
green. The variants subjected to cDNA
analysis are shown in the dark green rect-
angles.
(D) Balanced translocation between
chromosomes 4 and 17, with the break-
point disrupting TLK2 between exons 2
and 3, identified in one individual:
46,XX,t(4;17)(27;q23.2).seq[GRCh37]t(4;17)g.[chr4:pter_cen_122332907:: chr17:60,581,319_qter]g.[chr17_pter_cen_60,581,315::chr4:
122,332,920_qter].
(E) Pedigrees of individuals with inherited variants and photographs of probands and their affected mothers. Both mothers have facial
dysmorphism similar to their children. WT, wild-type at variant position.affected protein product: c.1286þ1G>T and c.1286þ
1G>A (Figure 1B; Table 1). From the 9 missense variants
identified in 11 unrelated individuals, 5 are located in
the catalytic domain of the protein and 3 in a coiled-coil
motif. One variant, c.890G>A (p.Gly297Asp), is located
outside a known functional domain, but affects a highly
conserved amino acid and was predicted pathogenic by
several in silico prediction programs, similar to other
missense variants (Figure 1C; Table S1). None of the
missense variants were present in the ExAC database,14
nor in our in-house database of variants identified in
healthy control subjects. The recently released gnomAD
database, containing WGS variants identified in control
subjects, reported only c.1636C>T (p.Arg546Trp) in a sin-
gle individual (allele frequency of0.000004). None of the
other missense variants were present in the gnomAD data-
base (Table 1).
For all but two variants (Table 1), the de novo status was
assessed by sequencing the parents of the proband. In
two individuals, variants were inherited from a similarly
affected parent, while all other variants (n ¼ 34) occurred
de novo. Detailed phenotyping revealed that both mothersThe Americacarrying a predicted loss-of-function (LOF) TLK2 variant
(Table 1) were mildly affected. The first mother (c.1460þ
2T>G) had mild neurodevelopmental delay and
speech delay. The second affected mother (c.1776_
1783delTGGTCTTT [p.Gly593Glufs*5]) had a low-normal
IQ level but was diagnosed with bipolar disorder. Both
had facial dysmorphism similar to their affected children
(Figure 1E). The inherited variants illustrate that the search
for a diagnosis should not always be restricted to de novo
mutations, in particular if individuals are only mildly
affected. Similar to the parents in this study, who were
never referred for genetic testing before investigation of
their child uncovered a TLK2 variant, we expect mutations
causing milder phenotypes to be present in the general
population. This could explain why, although TLK2
exhibits very strong constraint against LOF variants
(pLI ¼ 1), five LOF variants (low-coverage variants
excluded) have been reported in gnomAD, and a missense
variant—c.1636C>T (p.Arg546Trp)—that was reported
here as de novo variant, was present at very low allele fre-
quency in the population (aggregate minor allele fre-
quency of LOF and missense variants 0.000024).n Journal of Human Genetics 102, 1195–1203, June 7, 2018 1197
Table 1. Intragenic Variants in TLK2 (GenBank: NM_006852.3), Inheritance, and Presence in ExAC and gnomAD Databases
Subgroup cDNA Position Protein Position Inheritance RNA Analysis cMAF ExAC cMAF gnomAD
Predicted LOF c.37C>T p.Gln13* de novo no no LOF variants 5 LOF variants: 0.00002
c.181C>T p.Arg61* de novo no
c.202G>T p.Glu68* de novo no
c.685_688del p.Glu229Argfs*6 de novo no
c.777C>A p.Tyr259* de novo no
c.784C>T p.Arg262* de novo no
c.8321G>A unknown de novo no
c.907C>T p.Arg303* de novo no
c.968þ1del unknown de novo no
c.989C>A p.Ser330* de novo yes
c.1121þ1G>A unknown de novo no
c.11221G>T unknown de novo no
c.1286þ1G>T unknown de novo no
c.1286þ1G>A unknown de novo no
c.1460þ2T>G unknown inherited no
c.1550þ1G>A unknown de novo no
c.1651C>T p.Gln551* de novo no
c.1672dup p.Tyr558Leufs*4 de novo no
c.1720þ1G>Ta unknown de novo yes
c.1746delA p.Ala583Argfs*5 de novo no
c.1776_1783delTGGTCTTT p.Gly593Glufs*5 inherited no
c.18601G>T unknown unknown no
c.19722A>G unknown de novo no
c.2079þ1G>A unknown de novo no
Other variant types c.2092C>Ta p.Arg698* de novo yes 0 0
c.2170C>T p.Arg724* de novo no 0 0
c.890G>A p.Gly297Asp de novo no 0 0
c.1015C>T p.Arg339Trp de novob no 0 0
c.1016G>A p.Arg339Gln de novo no 0 0
c.1273G>A p.Glu425Lys unknown no 0 0
c.1412A>Ga p.His471Arg de novo no 0 0
c.1487A>Ga p.His496Arg de novob no 0 0
c.1636C>T p.Arg546Trp de novo no 0 0.000004
c.1819G>Aa p.Asp607Asn de novo no 0 0
c.1973C>G p.Pro658Arg de novo no 0 0
Identified balanced translocation (n ¼ 1) is not included in this table. Abbreviations: cMAF, cumulative minor allele frequency; LOF, loss-of-function
aVariant reported previously1
bRecurrent de novo variant identified in two unrelated individualsConsistent with the phenotypes of both affected
mothers, mild neurodevelopmental phenotypes accompa-
nied by language and motor delay were present in the ma-
jority of the 38 unrelated probands: 6% of the individuals
had normal IQ levels (85–100), 14% had borderline ID (IQ1198 The American Journal of Human Genetics 102, 1195–1203, Jun70–85), and from the 72% diagnosed with ID (IQ < 70),
most had mild ID (IQ 50–70) (Figure 2). Most of the
affected probands (22 males and 16 females) were children
at the time of last examination (median 8.0 years;
interquartile range 4.1–13.5 years); ages ranged betweene 7, 2018
Figure 2. Clinical Spectrum Associated
with TLK2 Variants
Overview of clinical features observed in
individuals with TLK2 variants.3 months and 29 years. Three individuals, who all had lan-
guage and motor delay, were too young for formal assess-
ment of their neurodevelopmental phenotype. In addition
to this, systematic evaluation of other clinical data, scored
by the referring clinician, showed a variety of overlapping
features (Figure 2, Table S2). Neurological problems
including hypotonia (37%), epilepsy (13%), and non-spe-
cific intracranial brain abnormalities (13%) (Table S3)
were observed. A broad range of behavioral disorders was
present (68%), with often severely affected social func-
tioning: tantrums (11 individuals), autism spectrum disor-
der (ASD; 11 individuals), attention-deficit disorder with or
without hyperactivity (ADHD; 5 individuals), and severe
social-emotional problems (6 individuals) were the most
commonly reported problems. Less frequently observed
were short attention span, pica disorder, aggression, obses-The American Journal of Human Gensive-compulsive disorder, and anxiety
in 11 individuals. Other recurrent fea-
tures included gastro-intestinal prob-
lems (constipation in 55%; severe
diarrhea in 8%), neonatal feeding
difficulties (42%), eye abnormalities
(refraction abnormality in 29%, stra-
bismus in 26%), musculoskeletal ab-
normalities (joint hypermobility in
21%; pes planus in 21%; toe walking
in 18%; scoliosis in 8%; contractures
of the hands in 8%), recurrent otitis
media (24%), hypertrichosis (16%),
and hoarse voice (8%). Abnormalities
of skull shape were observed in 31%
of probands (Figure 2, Tables S2 and
S4), with clinically proven craniosy-
nostosis being present in four
(11%) of them (Table S5). However,
sequence-based screening of 309
DNA samples from individuals with
mixed, genetically undiagnosed cra-
niosynostosis (Supplemental Subjects
and Methods, Table S6) did not
identify further case subjects, indi-
cating that TLK2 mutations are
a rare cause of craniosynostosis.
Growth parameters were frequently
abnormal (Figure 2). Short stature
was documented in 37%, micro-
cephaly in 24% (primary in 13%, sec-
ondary in 3%, and unknown age of
onset in 8%), and low body weight
in 13%. Three individuals (8%) were
overweight, with age of onset be-tween the ages of 2 and 12 years. Features reported in
only one or two individuals are summarized in Table S4.
In addition to the other clinical features, overlapping facial
dysmorphisms were present (Figures 3A and 3B). Most
frequently reported by clinicians were blepharophimosis
(82%), telecanthus (74%), prominent nasal bridge (68%),
broad nasal tip (66%), thin vermilion of the upper lip
(62%), and upslanting palpebral fissures (55%). Pointed
and tall chin (42%), epicanthal folds (42%), narrowmouth
(32%), high palate (30%), microtia, first degree (29%), pos-
teriorly rotated ears (29%), long face (27%), ptosis (21%),
and asymmetric face (16%) were observed in fewer than
half of the individuals.
Analysis of data from the ExAC database demonstrates
that TLK2 is extremely intolerant for LOF variants (pLI
score ¼ 1).14 In line with this observation, animal modelsetics 102, 1195–1203, June 7, 2018 1199
Figure 3. Facial Dysmorphism of Individ-
uals with TLK2 Variants
(A) Photographs of 21 unrelated individ-
uals with a loss-of-function variant in
TLK2, showing overlapping facial dysmor-
phism. Most frequently reported by clini-
cians were blepharophimosis, telecanthus,
prominent nasal bridge, broad nasal tip,
thin vermilion upper lip, and upward
slanted palpebral fissures. Pointed and tall
chin, epicanthal folds, narrow mouth,
high palate, microtia, posteriorly rotated
ears, long face, ptosis, and asymmetric
face were observed in fewer than half of
the individuals.
(B) Photographs of seven unrelated indi-
viduals with a missense or C-terminal trun-
cating variant in TLK2. Variant c.2170C>T
(p.Arg724*) is assigned to this subgroup,
since a premature stop codon is introduced
in the last exon. Facial dysmorphisms over-
lapped with dysmorphism observed in in-
dividuals with loss-of-function variants.
(C) Computational averaging of 33 facial
photographs of 22 subjects with LOF vari-
ants in TLK2 (left) compared with 22
gender- and age-matched control subjects
(right).
(D) Computational averaging of 11 facial
photographs of 8 subjects with missense
or C-terminal truncating variants in TLK2
(left) compared with 8 gender- and age-
matched control subjects (right).with depletion of TLK2 have been reported to have
severely disturbed cellular and developmental processes.
Drosophila with complete LOF of TLK were associated
with arrested nuclear divisions, causing apoptosis of the
cell.7 Tlk2-null mice were embryonically lethal due to
placental failure.15 In this study, we found several pre-
dicted LOF variants in affected individuals. To investigate
whether variants resulted in an aberrant transcript, we
synthesized cDNA from RNA extracted from fibroblast or
lymphoblastoid cell lines (Supplemental Subjects and
Methods, Table S7) from three individuals with different
variants: (1) c.989C>A (p.Ser330*), predicted to result1200 The American Journal of Human Genetics 102, 1195–1203, June 7, 2018in a truncated product leading to
nonsense-mediated decay (NMD); (2)
c.2092C>T (p.Arg698*), with a pre-
mature stop codon in the last exon
predicted to escape from NMD; and
(3) c.1720þ1G>T, a mutation pre-
dicted to affect splicing of exon 18.
To investigate the significance of
NMD for expression of TLK2 tran-
scripts, we treated fibroblasts (for
p.Ser330*) and lymphoblastoid cell
lines (for p.Ser330*, p.Arg698*, and
c.1720þ1G>T) with cycloheximide,
an inhibitor of NMD.16 Transcript sta-
bility of cDNA PCR products from
p.Ser330* and p.Arg698* individualsin the presence of cycloheximide was analyzed using a re-
striction enzyme assay targeting the wild-type transcript
and the results were confirmed using deep sequencing to
quantify relative levels of wild-type andmutant transcripts
(Supplemental Subjects and Methods). For fibroblast and
lymphoblastoid cell lines heterozygous for the p.Ser330*
variant, the mutant allele represented 15.8% and 21.5%
of transcripts, respectively, in the absence of cyclohexi-
mide, but rose to 37.7% and 48.5%, respectively, in
the presence of cycloheximide, supporting that this
variant is subject to NMD and causes haploinsufficiency
of TLK2. In contrast, wild-type and mutant transcripts
Figure 4. Analysis of TLK2 Transcripts in
Cell Lines
(A) Analysis of transcripts encoding
nonsense mutations c.989C>A (p.Ser330*)
and c.2092C>T (p.Arg698*) in cell lines of
affected individuals. Left panel shows
reverse transcriptase-PCR (RT-PCR) prod-
ucts of cDNA prepared from fibroblast and
lymphoblastoid cell lines of subject with
p.Ser330* variant, either in the presence
(þC) or absence (C) of cycloheximide
and incubated with ApoI (digests wild-
type allele). Central panel shows RT-PCR
of cDNA prepared from lymphoblastoid
cell line of subject with p.Arg698* variant,
in the presence (þC) or absence (C) of
cycloheximide and incubated with Hpy99I
(digests wild-type allele). Right panel
shows proportion (5standard deviation)
of variant alleles quantified by deep
sequencing of triplicate samples. Statistical testing of differences: *p ¼ 0.046; **p ¼ 0.011; NS, not significant.
(B)Analysis of transcriptswith canonical splice-sitemutationc.1720þ1G>T.Awild-type fragmentat 300bp inc.1720þ1G>T lymphoblas-
toid cells is observed as well as a second fragment at 130 bp, which is absent in control cDNA. An increase ofmutant transcript in cells was
present when treated with cycloheximide (þC), indicating that the aberrant transcript was subject to NMD. Sequencing of the 300 bp
(white box) and 130 bp (green box) fragments demonstrated skipping of exon 18 in the lower cDNA product. Abbreviations: Fibs, fibro-
blasts; EBV, lymphoblastoid cells; C/CHX, cycloheximide; WT, control cDNA.from lymphoblastoid cells of the individual heterozygous
for p.Arg698* did not show significant differences between
treated and untreated cells, supporting that the mutant
transcript escapes NMD due to its location within the
last coding exon of TLK2 (Figure 4A). Amplification of
cDNA from an individual with a splice-site variant
(c.1720þ1G>T) showed a full-length wild-type product
of 300 bp and an additional aberrant smaller product of
130 bp, consistent with skipping of exon 18. Direct
sequencing of this smaller fragment confirmed that
exon 17 spliced directly to exon 19, thereby producing
an out-of-frame transcript predicted to introduce a prema-
ture stop codon at the next amino acid position
(p.Ser517fs*1). Additionally, the intensity of the spliced
transcript increased when treated with cycloheximide,
indicating that the mutant transcript is subjected to
NMD (Figure 4B).
By analyzing TLK2 transcripts in cell lines of three
different individuals, we were able to confirm that tran-
scripts were subjected to NMD in two of them, causing hap-
loinsufficiency of TLK2. It is likely that comparable variants
predicted to cause LOF of TLK2 affect the transcript simi-
larly. The large number of identified individuals with
TLK2 variants allowed us to search for underlying patho-
genic mechanisms for the individuals with variants with
unknown effect, such as p.Arg698*. To assess this, we
divided our cohort in two subgroups and (1) performed a
structured genotype-phenotype analysis and (2) created
and compared computationally modeled faces. Subgroup
1 (n ¼ 25) included all probands carrying a predicted LOF
variant (nonsense, frameshift or canonical splice-site, or
balanced translocation) similar to variants p.Ser330* and
c.1720þ1G>T. Subgroup 2 (n ¼ 13) comprised individuals
with either missense variants or variants introducing a pre-
mature stop codon in the last exon of TLK2, such asThe Americap.Arg698*. Affected parents of probands with inheritedmu-
tations were not included in the subgroups. Next, we
compared frequencies of 40 different features and fre-
quencies of 15 facial dysmorphisms between the two
groups via a two-tailed Fisher’s exact test. This showed
that both clinical features and facial dysmorphisms were
remarkably similar between the two subgroups. From the
55 different features, none differed significantly between
the two subgroups (p < 0.05), even without correction for
multiple testing (Table S2). Second, averaged visualization
of facial dysmorphism by computational modeling of 33
photographs from 22 individuals in subgroup 1 compared
with 11 photographs from 8 individuals in subgroup 2 at
different ages (Supplemental Subjects and Methods)
showed consistent differences from a comparable number
of gender- and age-matched controls, including blepharo-
phimosis, telecanthus, broad nasal tip, and tall, pointed
chin (Figures 3C and 3D). Given this strong overlap in phe-
notypes and facial dysmorphic features between probands
with different type of mutations, it is likely that not only
LOF variants but also the majority of identified missense
variants and variants with a premature stop codon in the
last exon have only a single functional copy of TLK2.
Hence, we conclude that the predominant pathogenic
mechanism of these TLK2 mutations is haploinsufficiency.
Often mentioned together with TLK2 is its close interac-
tor TLK1. From birth, murine Tlk2 shows a similar expres-
sion pattern to the closely related paralog Tlk1 across many
tissues.15 Human TLK1 has 84% identity to TLK2 at the
protein level,3 and it was shown that TLK1 depletion leads
to extensive chromosome segregation defects in human
cells.17 Interestingly, TLK1 (MIM: 608438) is (similarly to
TLK2) intolerant for both missense and truncating muta-
tions in healthy individuals (significant z-scores of 3.84
[TLK1] and 5.67 [TLK2] and pLI [constraint] scores ofn Journal of Human Genetics 102, 1195–1203, June 7, 2018 1201
1.00 for both TLK1 and TLK2) (ExAC database).14 In
the literature, four de novo variants have been reported in
TLK1 (GenBank: NM_012290.4): c.74C>T (p.Pro25Leu)
in an individual with intellectual disability,1 c.1697T>C
(p.Met566Thr) in an individual with autism,18 c.1796C>G
(p.Ala599Gly) in an individual with a NDD and congenital
heart disease,19 and c.1101del (p.Lys367Asnfs*25) in an in-
dividual with schizophrenia.20 Importantly, none of these
variants are present in the ExACor gnomADdatabases. Tak-
ing this into account, it is possible that TLK1 variants could
contribute toNDDs, similar to the homologTLK2. In future
research, the exact role of TLK1 in NDDs should be further
explored.
In conclusion, we show that both de novo and inherited
mutations in TLK2 cause a distinct neurodevelopmental
disorder, hallmarked by mild developmental delay, a vari-
ety of behavioral disorders, severe gastro-intestinal prob-
lems, and facial dysmorphism. The identification of a large
number of individuals (n ¼ 40, including two affected
mothers) emphasizes the power and importance of data
sharing, allowing us to delineate the clinical phenotype
and to evaluate genotype-phenotype correlations. More
than two-thirds of the individuals were identified in two
relatively small countries: the Netherlands and the UK
(Figure S1). With an estimated prevalence of 1/566 (17/
9,625) of TLK2 variants in probands recruited to the
DDD study, it is expected that a larger number of individ-
uals with TLK2 variants is present world-wide. In future,
even more extensive data sharing than performed in this
study will be needed to further extend the TLK2 cohort.
By analyzing three cell lines of affected individuals, we
were able to confirm that at least two variants act through
a heterozygous loss-of-function mechanism (haploinsuffi-
ciency). The phenotypes of these individuals and others
with comparable loss-of-function variants significantly
overlapped with phenotypes of individuals with other
variant types, providing further evidence for the underly-
ing disease mechanism of the TLK2 variants. Given the ge-
netic and functional similarities between TLK2 and TLK1,
further research should focus on the potential role of
TLK1 mutations in developmental disorders.Supplemental Data
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